Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A00686-49 | Registry Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Plateforme PRISME | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Objective quantitative primary endpoints are lacking in Clinical trials in intellectual disability. We propose to develop quantitative interactive attention evaluation criteria in patients with intellectual disability by using games on touchscreen and or eye tracking.
The aim of the study is to develop and validate quantitative interactive attention evaluation criteria by using games on touchscreen and or eye tracking in patients with intellectual disability. Tests will have to be suitable whatever severity and etiology of intellectual disability. Tests have to evaluate attention and concentration troubles in intellectual disability.Once validated, tests could be used as outcome measures in clinical trials and as cognitive reeducation tools in intellectual disability.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| X fragile syndrome patients | Other |
| |
| Angelman syndrome patients | Other |
| |
| Rett syndrome patients | Other |
| |
| Patients with other genetic rare syndromes with intellectual d | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quantitative attention evaluation criteria in intellectual disability | Device | Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer) |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between number of successful attempts and intellectual disability evaluated by Intelligence quotient (IQ) or age of development | Test performed 1 time during a visit (1 day) can be repeated (for a maximum of 15 patients) within 3 months if an adaptation of the interactive tool is necessary | up to 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Maximal reached level for each test | up to 3 months | |
| Number of errors during the test | up to 3 months | |
| Time to reach each level of the test |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| CHARLES Perrine, MD PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital La Pitié-Salpêtrière | Paris | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008607 | Intellectual Disability |
| ID | Term |
|---|---|
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| up to 3 months |
| Time to reach maximum level of the test | up to 3 months |
| Total test duration | up to 3 months |
| Fixing time for eye tracking | up to 3 months |
| Successful test numbers in each level | up to 3 months |
| Correlation with Intelligence quotient (IQ) or age of development according to intellectual disability severity | up to 3 months |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |